Skip to main content

Table 1 General characteristics of patients with pT3N0M0 stage thoracic esophageal squamous cell carcinoma

From: Unresected small lymph node assessment predicts prognosis for patients with pT3N0M0 thoracic esophageal squamous cell carcinoma

Characteristic Total (n=294) CT-suspect group (n=84) CT-negative group (n=210) χ2 P value
Sex     3.284 0.070
 Male 228 (77.6%) 71 (84.5%) 157 (74.8%)   
 Female 66 (22.4%) 13 (15.5%) 53 (25.2%)   
Age (years)     0.721 0.396
 <60 141 (48.0%) 37 (44.0%) 104 (49.5%)   
 ≥60 153 (52.0%) 47 (56.0%) 106 (50.5%)   
Tumor location     0.411 0.814
 Upper thoracic 70 (23.8%) 19 (22.6%) 51 (24.3%)   
 Middle thoracic 163 (55.4%) 49 (58.3%) 114 (54.3%)   
 Lower thoracic 61 (20.8%) 16 (19.0%) 45 (21.4%)   
Surgical approach     1.723 0.189
 Ivor–Lewis 92 (31.3%) 31 (36.9%) 61 (29.0%)   
 McKeown 202 (68.7%) 53 (63.1%) 149 (71.0%)   
Length of lesion     0.311 0.577
 <4 cm 171 (58.2%) 39 (46.4%) 90 (42.9%)   
 ≥4 cm 123 (41.8%) 45 (53.6%) 120 (57.1%)   
Angioinvasion     0.707 0.400
 No 272 (92.5%) 76 (90.5%) 196 (93.3%)   
 Yes 22 (7.5%) 8 (9.5%) 14 (6.7%)   
Perineural invasion     0.973 0.324
 No 56 (19.0%) 65 (77.4%) 173 (82.4%)   
 Yes 238 (81.0%) 19 (22.6%) 37 (77.4%)   
No. of removed LNs     1.875 0.171
 <15 88 (29.9%) 30 (35.7%) 58 (27.6%)   
 ≥15 206 (70.1%) 54 (64.3%) 152 (72.4%)   
No. of dissected LN stations     0.702 0.402
 <6 91 (31.0%) 29 (34.5%) 62 (29.5%)   
 ≥6 203 (69.0%) 55 (65.5%) 148 (70.5%)   
Tumor grade     0.002 0.999
 Well-differentiated 63 (21.4%) 18 (21.4%) 45 (21.4%)   
 Moderately differentiated 136 (46.3%) 39 (46.4%) 97 (46.2%)   
 Poorly differentiated 95 (32.3%) 27 (32.1%) 68 (32.4%)   
Adjuvant therapy     1.827 0.401
 No 139 (47.3%) 41 (48.8%) 98 (46.7%)   
 Chemotherapy 132 (44.9%) 34 (40.5%) 98 (46.7%)   
 Radiotherapy/Chemoradiotherapy 23 (7.8%) 9 (10.7%) 14 (6.7%)   
  1. CT computed tomography; LN lymph node